Navigation Links
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Date:6/13/2008

rious infections and hypersensitivity reactions including anaphylaxis. The most common adverse events reported in clinical studies were upper respiratory tract infection, nasopharyngitis, headache and hypertension. Increases in liver function tests (ALT and AST) were seen in some patients; these increases were generally mild and reversible, with no hepatic injuries or any observed impact on liver function.

About IL-6

IL-6 is a common protein found in all joints in the body and is a natural substance that can raise inflammation. Everyone has IL-6 in their body, but people with RA may have too much. If approved, ACTEMRA will be the first and only medication to specifically target IL-6 in patients with RA.

About Rheumatoid Arthritis

Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to irreversible joint destruction and disability. Characteristics of RA include redness, swelling, pain and movement limitation around joints of the hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms of RA include fatigue, decreased hemoglobin, osteoporosis and may contribute to shortening life expectancy by affecting major organ systems. After 10 years, less than 50 percent of patients can continue to work or function normally on a daily basis. RA affects more than 21 million people worldwide with approximately 1.3 million adults affected in the United States.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative produ
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
4. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
5. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
6. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
7. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
10. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
11. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Conn. , Sept. 19, 2014 UBM ... , a leading online community to help oncologists and ... information available regarding the use of targeted therapies and ... cancer research and treatment.  Every September, ... a way to raise awareness about blood cancers—helping to ...
(Date:9/19/2014)... WALTHAM, Mass. , Sept. 19, 2014  Alere ... in rapid diagnostics, issued the following statement today in ... Combating Antibiotic-Resistant Bacteria. "As the global leader ... President for establishing a national strategy to address the ... continuing to work with the Administration on initiatives to ...
(Date:9/19/2014)... and ORLANDO, Fla. , Sept. ... Inspire therapy continues to grow, with the publication of ... on-line in Otolaryngology – Head and Neck ... a worsening of both objective and subjective measures of ... attribute Inspire therapy for the reduction in obstructive sleep ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... arm demonstrated a, significant survival benefit as well ... Mass., Aug. 27 Millennium: The Takeda,Oncology Company today ... Phase III VISTA(1) trial in this week,s edition of ... significant survival,benefit and a 30 percent complete remission (CR) ...
... Tourism Commission,launched its new free online Quality Care ... http://www.OregonQCare.com ., Oregon Q Care is ... and,hospitality industry through enhanced employee education. By emphasizing,the ... equip,employees with tools and resources to better serve ...
Cached Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Oregon Tourism Commission Unveils New Online Customer Service Training Program 2
(Date:9/20/2014)... York, New York (PRWEB) September 20, 2014 ... power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological ... that yet another insurer has announced plans to ... statement posted on its website last month, Harrisburg, ... procedures effective November 1, 2014. The insurer said ...
(Date:9/20/2014)... Traditionally dentists have advised their patients against drinking coffee ... is re-visiting that advice and changing his stance after considering ... have on oral health. “There’s good news and great news,” ... beneficial in protecting against gum disease, and red wine can ... was from the September 2014 issue of Boston University ...
(Date:9/20/2014)... September 20, 2014 Earlier this week, Home ... may have had their credit card information pilfered by hackers, ... a slew of headline articles like this one ... only eye opening numbers. , “Most people tend to ... like it’s a way to score a game,” says Joe ...
(Date:9/20/2014)... The Arizona Advanced Manufacturing ... National Manufacturing Day by opening its doors to the ... additive manufacturing labs will be offered between 10 a.m. ... Southern and Dobson campus (1833 W. Southern Ave, Mesa, ... , The AzAMI at MCC was established in the ...
(Date:9/20/2014)... 2014 The children of Branches now ... active play they need. An empty lot at the ... Campus was transformed into a kid-designed playspace in less ... from Branches (@BranchesFL), ESPN (@TeamESPN), Disney (@CitizenDisney), area residents ... a playground is more than a playground. It’s a ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 2Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 3Health News:Volunteers Improve Miami Kids’ Lives and Futures with Play 4
... MiLife Coaching Limited,announces the publication of their third ... weight management coaching system to boost employee,health and ... , MiLife is an ... physical activity management system. It incorporates biofeedback and,the ...
... season prompts tips on how to avoid most common cause ... -- If you didn,t know better, you could confuse carbon ... U.S. Environmental Protection Agency has a new fact sheet out ... deaths and 15,000 visits to the emergency room caused each ...
... Eklin Medical Systems, a leading,provider of digital ... and practice management software (VIA) for veterinary,care, introduced ... North American,Veterinary Conference being held in Orlando, January ... economical solution for digital imaging based on Eklin,s ...
... INSM ), a developer of follow-on ... dedicated to the development of, diagnosis and prevention of ... that the European Medicines Agency (EMEA) has granted Premacure ... mecasermin rinfabate, for the prevention of retinopathy of prematurity ...
... Varian, Inc.,(NasdaqGS: VARI) plans to release its financial ... Pacific Time (PT) on Wednesday February 4,2009. A live ... to,review those quarterly results is scheduled to follow at ... That live webcast can be accessed from Varian, ...
... 21 Horphag Research, exclusive worldwide,suppliers of Pycnogenol(R) ... earned the 2008 Frost & Sullivan North American ... This award, presented,last week at Frost & Sullivan,s ... Research,s efforts in conducting numerous research projects,over the ...
Cached Medicine News:Health News:MiLife Proven to Boost Vitality of Unilever Employees Using Smart Affordable Technology 2Health News:Eklin Launches New RapidStudy(TM) CDx Digital Radiography System at NAVC 2Health News:Eklin Launches New RapidStudy(TM) CDx Digital Radiography System at NAVC 3Health News:Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants 2Health News:Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants 3Health News:Horphag Research Receives 2008 Frost & Sullivan North American Health Ingredients Excellence In Research Award 2Health News:Horphag Research Receives 2008 Frost & Sullivan North American Health Ingredients Excellence In Research Award 3
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
... Autostat™II Rheumatoid Factor IgM enzyme linked immunosorbent ... (RF IgM). Enzyme-linked immunosorbent assay method for ... Factor in human serum. The results of ... as an aid in the diagnosis of ...
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
... The GALILEI Dual Scheimpflug Analyzer is a ... and three dimensional analysis of the anterior ... Channel Scheimpflug Camera and a Placido Disk. ... technologies: Placido imaging furnishes high accuracy curvature ...
Medicine Products: